{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-26-000016","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-07-30T20:05:37+00:00","discovered_at":"2026-07-30T20:06:18.375453+00:00","generated_at":"2026-07-30T20:07:10.373458+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PTC Therapeutics Q2 net income $83.5M, raises FY product revenue guidance to $850-950M","bullets":["Q2 total revenue $361M (product $239M) includes $50M Novartis milestone; net income $83.5M vs net loss $64.8M YoY.","FY 2026 product revenue guidance raised to $850-950M (from $750-850M); total revenue guidance raised to $1.18-1.28B.","Sephience Q2 revenue $151M (+21% QoQ); 1,647 patients on therapy; Translarna $42.2M, Emflaza $24.6M, Evrysdi royalty $71.1M.","Issued $550M senior convertible notes due 2031 at 0% coupon, 40% conversion premium; repurchased majority of 1.5% notes due 2026. Cash $2.23B.","Pipeline: PTC303 (MSH3) targeting Huntington's, clinic entry 2027; PTC612 (NLRP3) Phase 1 initiated; vatiquinone PROVE-FA study Q3 2026; votoplam PIVOT-HD 24-month results showed 52% disease slowing."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-26-000016","json":"https://secwatch.observer/filing/0001070081-26-000016.json","markdown":"https://secwatch.observer/filing/0001070081-26-000016.md","text":"https://secwatch.observer/filing/0001070081-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/0001070081-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:07:10.373458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}